FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/Semaglutide Study Aims to Boost Sperm Health in Overweight Men
返回研究图书馆

Semaglutide Study Aims to Boost Sperm Health in Overweight Men

November 20, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

Semaglutide Study Aims to Boost Sperm Health in Overweight Men

A new clinical trial set to explore how semaglutide—a popular weight-loss medication—might improve sperm concentration and overall reproductive health in overweight men has been announced. The study, which will be conducted at Copenhagen University Hospital at Herlev, is currently not recruiting participants but aims to provide valuable insights into the potential benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for male fertility.

Background

Overweight and obesity are increasingly recognized as significant risk factors for reproductive issues in men. These conditions can lead to functional hypogonadism, a condition where testosterone levels drop below normal due to the negative impact of excess body fat on hormone production. This reduction in testosterone can negatively affect sperm count and quality, leading to infertility.

Current interventions such as lifestyle changes and weight loss programs often struggle with long-term adherence, making it challenging for men to maintain improved reproductive health over time. However, recent research has highlighted the potential benefits of GLP-1RAs like semaglutide in not only promoting significant weight loss but also improving metabolic markers that influence hormone levels.

Key Details

The upcoming Phase 2 clinical trial will specifically examine how semaglutide affects sperm concentration and overall reproductive health in overweight men struggling with infertility. The study, identified by the ClinicalTrials.gov identifier NCT07946796, plans to compare the effects of semaglutide against a placebo treatment over an extended period.

Participants will be randomly assigned to receive either semaglutide (Wegovy®) or a saline placebo. Researchers aim to assess how these treatments influence sperm count and quality, as well as other reproductive health markers like testosterone levels. The study's primary objective is to determine if GLP-1RAs can enhance fertility in overweight men through both direct hormonal effects and indirect benefits related to weight loss.

Key Takeaways

  • Weight Loss and Fertility: Semaglutide may offer a promising new avenue for improving reproductive health by addressing obesity-related hypogonadism.
  • Mechanisms of Action: GLP-1RAs could directly influence hormone levels while also indirectly supporting fertility through weight management benefits.
  • Clinical Evidence Needed: This study will provide crucial data on the efficacy and safety of semaglutide for male infertility, paving the way for future research and clinical applications.
  • Patient Impact: If successful, this treatment could offer a more sustainable solution compared to traditional lifestyle interventions in managing reproductive health issues linked to obesity.

What This Means

For the peptide community, this study represents an important step forward in understanding how GLP-1RAs can be leveraged beyond weight management to address broader health concerns like male infertility. As researchers continue to explore the multifaceted benefits of these peptides, there is potential for significant advancements in personalized medicine and patient care.

The findings from this trial could also influence regulatory considerations around peptide therapy usage and expand the scope of FDA regulation on GLP-1RAs, potentially leading to new guidelines or approvals that benefit both patients and clinicians. This research underscores the growing importance of peptide-based treatments in addressing complex health issues and highlights the need for ongoing investigation into their full therapeutic potential.

---

Source: ClinicalTrials.gov — Published 2026-11-18

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。